Keep an eye on cruise stocks like Norwegian Cruise Line (NCLH). For one, according to Reuters, travelers have been booking cruises for 2024 at “greater volumes” than even before the pandemic. About 35.7 million consumers are expected to cruise this year alone, up from...
Apple (AAPL) looks appealing at current prices. Last trading at $169.67, it’s back to strong support, where it typically bounces back. Helping, Wedbush analyst Dan Ives has an outperform rating on the stock, with a price target of $250. As noted by...
On March 28, we noted, “With gold quickly approaching $2,200, keep an eye on Newmont Mining (NEM). At the moment, it’s consolidating at $34. But with gold on the run, we believe NEM could break significantly higher from here.” With gold now up to $2,350, NEM is now up...
by Ian Cooper Gold prices are still rocketing higher. Last checked, the metal was above $2,300 and could see $2,500 this year. For one, central bank buying isn’t showing any signs of cooling off, with China buying even more for the seventeenth month in a row, says The...
Keep an eye on Ulta (ULTA). Over the last few days, the stock gapped from about $524.84 to $444.75 thanks to soft guidance. As noted by Seeking Alpha, “The company noted that it has seen a slowdown in demand across beauty categories. In terms of guidance, Ulta Beauty...
Viking Therapeutics (VKTX) could be the next big moneymaker with obesity drugs. As we noted on March 14, “Keep an eye on Viking Therapeutics (VKTX) again,” we said on March 14. The first time we mentioned VKTX here, it traded at around $36.20. Weeks later, it would...
Marvell Technology (MRVL) is just starting to pivot higher again. Last trading at $73.59, I’d like to see MRVL retest its prior high. Helping, the company recently declared a quarterly dividend of six cents, payable on May 1 to shareholders of record as of April...
Snowflake (SNOW) gapped from about $240 to a low of $160. All after issuing guidance that fell short of expectations and the departure of CEO Frank Slootman. However, it looks like most of the negativity has been priced in. Helping, insiders are buying the dip. ...
by Ian Cooper Cannabis stocks could see higher highs. For one, as we near the U.S. elections, we could hear more about potential legalization. After all, it’s a hot topic, and about 70% of the population wants to see legalization. Two, Vice President Kamala...
Keep an eye on Altimmune (ALT). After pulling back from about $15 to $8, it’s starting to pivot higher again. From its last traded price of $10.18, I’d like to see it retest $15 initially. It’s also working on an obesity drug, with good results, as well. Citing data...